Cytokinetics Announces Positive Results from a Pivotal Phase 3 Clinical Trial of Aficamten

We recently became enthusiastic about Cytokinetics’ (CYTK) current clinical trial results. A few days ago, Cytokinetics announced positive results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

Why the Great Enthusiasm?

The following has been behind our enthusiasm . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.